Rohan Penmetcha, DO
Cardiovascular Disease · Cedar Rapids, IANPI 1841603172
Payments from drug & device makers
What this record shows
This record is dominated by food and beverage: $3,271 of the $5,291 with a category attached, or 61.8%. 20 manufacturers reported payments, led by Abbott at 48.2% of the total. Reporting peaked in 2019 at $3,682 and has fallen 94.8% since, to $190 in 2025.
Across 145 payments — averaging $36.49 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Abbott$3K
- Pfizer$611
- Novartis$345
- Medtronic$260
- Johnson & Johnson$209
- Astellas Pharma US Inc$208
- plus $1K from 14 others
What the payments were for
- Travel & lodging$1,84935%
- Food & beverage$3,27162%
- Education$1713%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Abbott | 29 | $2,552 |
| Pfizer | 26 | $611 |
| Novartis | 21 | $345 |
| Medtronic(2 entities) | 6 | $260 |
| Johnson & Johnson | 13 | $209 |
| Astellas Pharma US Inc | 5 | $208 |
| AstraZeneca | 11 | $166 |
| Cardiovascular Systems Inc. | 1 | $145 |
| Edwards Lifesciences | 1 | $130 |
| Vifor Pharma, Inc. | 1 | $125 |
| Boehringer Ingelheim | 5 | $87 |
| Amarin Pharma, Inc. | 4 | $86 |
| Boston Scientific | 4 | $85 |
| Amgen | 5 | $84 |
| E.r. Squibb & Sons, L.L.C. | 5 | $70 |
| Bayer | 3 | $56 |
| Regeneron Healthcare Solutions, Inc. | 2 | $27 |
| Bridgebio Pharma, Inc. | 1 | $16 |
| Esperion Therapeutics, Inc. | 1 | $16 |
| Actelion Pharmaceuticals US, Inc. | 1 | $13 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Ensite Cardiac Mapping System$1,492
- Biocor Stented Tissue Valve$165
- Confirm Rx$153
- Coronary Orbital Atherectomy System$145
- VYNDAQEL$131
- Edwards SAPIEN 3 Transcatheter Heart Valve$130
- HeartMate$125
- Veltassa$125
- CoreValve Evolut$121
- ELIQUIS$111
How this compares
$5,291 in reported general payments places this provider in the 80th percentile of 142 cardiovascular disease providers in Iowa.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 323 | $381,866 |
| XareltoRivaroxaban | 88 | $107,076 |
| Repatha SureclickEvolocumab | 85 | $61,049 |
| JardianceEmpagliflozin | 56 | $59,555 |
| VascepaIcosapent Ethyl | 49 | $24,329 |
| EntrestoSacubitril/Valsartan | 12 | $14,893 |
| Metoprolol Succinate | 676 | $9,209 |
| FarxigaDapagliflozin Propanediol | 12 | $7,971 |
| Praluent PenAlirocumab | 14 | $7,121 |
| Ezetimibe | 228 | $5,129 |
| Atorvastatin Calcium | 572 | $5,082 |
| BrilintaTicagrelor | 11 | $4,825 |
| Rosuvastatin Calcium | 512 | $4,701 |
| Nebivolol Hcl | 56 | $3,244 |
| Diltiazem 24hr Er (Cd)Diltiazem Hcl | 97 | $2,784 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerEliquis | $611 | $381,866323 claims |
| Johnson & JohnsonXarelto | $209 | $107,07688 claims |
| Boehringer IngelheimJardiance | $87 | $59,55556 claims |
| NovartisEntresto | $345 | $14,89312 claims |
| AstraZenecaFarxiga, Brilinta | $166 | $12,79623 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 142 cardiovascular disease providers in Iowa.
Other cardiovascular disease in Cedar Rapids
- Tyler RasmussenCedar Rapids$37K
- Matthew McMahonCedar Rapids$35K
- Amandeep Singh DhaliwalCedar Rapids$2K
- Brian OlshanskyIowa City$219K
- Troy HounshellWest Des Moines$164K
- Enrico MartinWest Des Moines$113K
- Gursukhman Deep SidhuDavenport$60K
- Suzanne FeigofskyWest Des Moines$59K
- Jennifer RobinsonIowa City$37K
- Craig StarkDes Moines$28K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.